Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)
Josep M. Llovet, Philippe Merle, Karl Heinz Weiss, Thomas Yau, Paul J. Ross, Vincenzo Mazzaferro, Jean–Frédéric Blanc, Yuk Ting, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gérolami, Jean‐François Dufour, Edward Gane, Baek‐Yeol Ryoo, Markus Peck‐Radosavljevic, Thông Dao, Winnie Yeo, Wisut Lamlertthon, Satawat Thongsawat, Michael Teufel, Heiko Krissel, Ho Yeong Lim (2016). Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC). Spiral (Imperial College London), 63
